Drug Profile
Imlunestrant - Eli Lilly and Company
Alternative Names: Imlunestrant tosylate - Eli Lilly and Company; LY-3484356Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Azetidines; Benzopyrans; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Phenyl ethers; Quinolines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- No development reported Endometrial cancer
Most Recent Events
- 28 Feb 2024 Eli Lilly completes a phase I pharmacokinetics trial in Healthy volunteers (PO) in the US (NCT05440344)
- 05 Dec 2023 Updated efficacy and adverse events data from a Ia/Ib EMBER trial presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 05 Dec 2023 Efficacy and adverse events data from a phase III EMBER-3 trial in Breast cancer released by Eli Lilly and Company